Skip to content

Study · Randomized controlled trial · n = 44 · 2022

4 results

Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.

Schmidt S, Frandsen CS, Dejgaard TF, Vistisen D, Halldórsson T, Halldórsson T, Olsen SF, Jensen JB, Madsbad S, Andersen HU, Nørgaard K

Diabetes, obesity & metabolism17 Oct 2021Cited by 25 (Europe PMC)

PMID34595827 (opens in a new tab)DOI10.1111/dom.14567 (opens in a new tab)PepBankPUB-34595827
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight adults with insulin pump-treated type 1 diabetes, liraglutide reduced fat mass versus placebo (-4.6 kg versus -0.3 kg; between-group P < 0.001).

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide lowered body fat more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal fat mass change
    Study

    n = 44

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg daily · 26 weeksAs given in this study (human).

    Measurements

    Fat mass change
    −4.6 kg
    liraglutide
    Fat mass change
    −0.3 kg
    placebo

    Source sentences

    Summary
    Total fat and lean body mass decreased in liraglutide-treated participants (fat mass -4.6 kg [95% confidence interval {CI} -5.7; -3.5], P < 0.001; lean mass -2.5 kg [95% CI -3.2;-1.7], P < 0.001), but remained stable in placebo-treated participants (fat mass -0.3 kg [95% CI -1.3;0.8], P = 0.604; lea…
    1 context sentence
    Summary · context
    A 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight adults with insulin pump-treated type 1 diabetes, liraglutide reduced lean mass versus placebo (-2.5 kg versus 0.0 kg; between-group P < 0.001).

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide lowered lean body mass more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseLean body mass change
    Study

    n = 44

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg daily · 26 weeksAs given in this study (human).

    Measurements

    Lean mass change
    −2.5 kg
    liraglutide
    Lean mass change
    0 kg
    placebo

    Source sentences

    Summary
    Total fat and lean body mass decreased in liraglutide-treated participants (fat mass -4.6 kg [95% confidence interval {CI} -5.7; -3.5], P < 0.001; lean mass -2.5 kg [95% CI -3.2;-1.7], P < 0.001), but remained stable in placebo-treated participants (fat mass -0.3 kg [95% CI -1.3;0.8], P = 0.604; lea…
    1 context sentence
    Summary · context
    A 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight adults with insulin pump-treated type 1 diabetes, energy intake fell by 1.1 MJ with liraglutide and 0.9 MJ with placebo, with no significant between-group difference (P = 0.42).

    In plain wordsIn overweight adults with type 1 diabetes, total energy intake did not differ significantly between liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeTotal energy intake change
    Study

    n = 44

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1.8 mg daily · 26 weeksAs given in this study (human).

    Measurements

    Energy intake change
    −1.1 MJ
    liraglutide
    Energy intake change
    −0.9 MJ
    placebo

    Source sentences

    Summary
    Participants reduced their energy intake numerically more in the liraglutide arm (-1.1 MJ [95% CI -2.0;-0.02], P = 0.02) than in the placebo arm (-0.9 MJ [95% CI -2.0;0.1], P = 0.22), but the between-group difference was statistically insignificant (P = 0.42).
    1 context sentence
    Summary · context
    A 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight adults with insulin pump-treated type 1 diabetes, energy from added sugars decreased by 27% with liraglutide versus an increase of 14% with placebo (P = 0.004).

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide lowered added sugar intake while it rose with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseEnergy from added sugars
    Study

    n = 44

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1.8 mg daily · 26 weeksAs given in this study (human).

    Measurements

    Change in energy from added sugars
    −27%
    liraglutide
    Change in energy from added sugars
    14%
    placebo

    Source sentences

    Summary
    However, energy derived from added sugars decreased by 27% in the liraglutide arm compared with an increase of 14% in the placebo arm (P = 0.004).
    1 context sentence
    Summary · context
    A 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.